**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79895

**Manuscript Type:** SYSTEMATIC REVIEWS

**Correlation between COVID-19 and hepatitis B: A systematic review**

He YF *et al*. Correlation between COVID-19 and hepatitis B

Yan-Fei He, Zhi-Gang Jiang, Ni Wu, Ning Bian, Jun-Lin Ren

**Yan-Fei He, Ni Wu, Ning Bian,** Health Management Center, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China

**Zhi-Gang Jiang,** Department of Statistics, Zunyi Medical University, Guizhou 563006, Guizhou Province, China

**Jun-Lin Ren,** Department of Infection Control, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China

**Author contributions:** He YF designed the study, reviewed the literature, and drafted the manuscript; Jiang ZG and Wu N retrieved and summarized the literature; Ren JL and Bian N advised on the review and reviewed the final manuscript; and all authors have read and approved the final manuscript.

**Corresponding author: Yan-Fei He, MD, Associate Chief Physician, Doctor,** Health Management Center, The Sixth Medical Center, Chinese PLA General Hospital, No. 6 Fucheng Road, Haidian District, Beijing 100048, China. heyanfeilc@163.com

**Received:** September 11, 2022

**Revised:** October 29, 2022

**Accepted:** November 19, 2022

**Published online:** December 14, 2022

**Abstract**

BACKGROUND

There is growing evidence that patients with coronavirus disease 2019 (COVID-19) frequently present with liver impairment. Hepatitis B virus (HBV) remains a major public health threat in current society. Both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HBV can cause liver damage, and current findings on whether HBV infection increases disease severity in COVID-19 patients are inconsistent, and whether SARS-CoV-2 infection accelerates hepatitis B progression or leads to a worse prognosis in hepatitis B patients has not been adequately elucidated.

AIM

To explore the complex relationship between COVID-19 and hepatitis B in order to inform the research and management of patients co-infected with SARS-CoV-2 and HBV.

METHODS

An experienced information specialist searched the literature in the following online databases: PubMed, China National Knowledge Infrastructure, Google Scholar, Scopus, Wiley, Web of Science, Cochrane, and ScienceDirect. The literature published from December 2019 to September 1, 2022 was included in the search. We also searched medRxiv and bioRxiv for gray literature and manually scanned references of included articles. Articles reporting studies conducted in humans discussing hepatitis B and COVID-19 were included. We excluded duplicate publications. News reports, reports, and other gray literature were included if they contained quantifiable evidence (case reports, findings, and qualitative analysis). Some topics that included HBV or COVID-19 samples but did not have quantitative evidence were excluded from the review.

RESULTS

A total of 57 studies were eligible and included in this review. They were from 11 countries, of which 33 (57.9%) were from China. Forty-two of the 57 studies reported abnormalities in liver enzymes, three mainly reported abnormalities in blood parameters, four indicated no significant liver function alterations, and another eight studies did not provide data on changes in liver function. Fifty-seven studies were retrospective and the total number of co-infections was 1932, the largest sample size was 7723, and the largest number of co-infections was 353. Most of the studies suggested an interaction between hepatitis B and COVID-19, while 12 studies clearly indicated no interaction between hepatitis B and COVID-19. Six of the 57 studies clearly reported HBV activation. Six studies were related to liver transplant patients.

CONCLUSION

There is some association between COVID-19 and hepatitis B. Future high-quality randomized trials are needed to further elucidate the interaction between COVID-19 and hepatitis B.

**Key Words:** COVID-19; SARS-CoV-2; Hepatitis B virus; Chronic hepatitis B; Liver injury; Co-infection

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** He YF, Jiang ZG, Wu N, Bian N, Ren JL. Correlation between COVID-19 and hepatitis B: A systematic review. *World J Gastroenterol* 2022; 28(46): 6599-6618

**URL:** <https://www.wjgnet.com/1007-9327/full/v28/i46/6599.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v28.i46.6599

**Core Tip:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis B virus (HBV) infections are two major current global public health crises. Both infection with SARS-CoV-2 and infection with HBV can cause liver damage. There are conflicting views on whether HBV infection aggravates the prognosis of patients with coronavirus disease 2019 (COVID-19). There is a potential association between COVID-19 and hepatitis B. Clarification of this association could benefit these special patients with SARS-CoV-2 and HBV co-infection.

**INTRODUCTION**

Since the outbreak of coronavirus disease 2019(COVID-19), there has been increasing evidence that patients with COVID-19 frequently present with hepatic impairment[1-3]. This may be caused by pre-existing liver disease, viral infection of hepatocytes, and certain medications. Hepatitis B virus (HBV) remains a major current public health threat to society, with approximately 300 million people chronically infected worldwide[4]. Since both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HBV can cause liver damage, current findings on whether HBV infection increases disease severity in patients with COVID-19 are inconsistent, with some reports suggesting that co-infection with SARS-CoV-2 and HBV has no effect on the course and prognosis of COVID-19[5,6], while several studies have shown that patients with SARS-CoV-2 and HBV co-infection are more likely to have serious outcomes[7-9]. Does pre-existing HBV infection increase susceptibility to SARS-CoV-2 infection, leading to more severe disease and a worse prognosis? Conversely, does SARS-CoV-2 infection accelerate the progression of hepatitis B or lead to worse outcomes? The potential association between hepatitis B and COVID-19 has not been fully elucidated, so it is important and interesting to understand how COVID-19 and hepatitis B interact with each other. In order to elucidate this complexity, we summarize almost all current clinical studies to provide a detailed description of the interaction between COVID-19 and hepatitis B, possible mechanisms, and clinical interventions to provide a reference for the clinical management of these special patients.

**MATERIALS AND METHODS**

***Identification of research questions***

Does SARS-CoV-2 and HBV co-infection have any effect on the course and prognosis of COVID-19? And *vice versa*, does COVID-19 accelerate the progression of hepatitis B and lead to a severe prognosis?

***Identification of relevant types of evidence***

The literature published from December 2019 to September 1, 2022 was included in the search. To avoid missing any relevant and important literature, we used an inclusive search strategy. An experienced information specialist searched the literature in the following online databases: PubMed, China National Knowledge Infrastructure, Google Scholar, Scopus, Wiley, Web of Science, Cochrane, and ScienceDirect. We also searched medRxiv and bioRxiv for gray literature and manually searched the references of the included studies to further ensure the comprehensiveness of the search. Articles that met the criteria in the *Reference Citation Analysis* (https://www.referencecitationanalysis.com) were also included in this review. Articles performed in humans and discussing SARS-CoV-2 in patients with hepatitis B and HBV in COVID-19 patients were included. Detailed search strategies are shown in Supplementary material.

***Study selection***

Several types of articles were included after our initial search, including case reports, case series, qualitative studies, and systematic and scoping reviews. We excluded repetitive publications. Articles containing more complete descriptions of the data were used for data charting. News articles, case reports, survey results, qualitative analyses, and other gray literature were also included in our review if they contained quantifiable evidence. We read the full text, synthesized the relevant evidence, and organized the literature thematically. All five authors participated in the discussion and decided on a theme. Some topics that included HBV or COVID-19 samples but did not have quantitative evidence were also excluded from the review. Figure 1 shows a visual representation of inclusion workflow.

***Data charting***

As of September 1, 2022, we retrieved 1136 publications, adding six manually retrieved papers for a total of 1142. We tested 139 full-text articles for eligibility after being screened by the above inclusion criteria, and 57 were finally included in this review (Figure 1). Two independent reviewers extracted data from the full-text papers of eligible studies, including the name of the first author, publication month and year, country of the study, number of included patients, number of SARS-CoV-2 and HBV co-infections, main biochemical characteristics of co-infected patients, their clinical outcome (death or survival), and main conclusion of each study. A summary of information on the included studies is presented in Table 1[9-60], and details of important parameters are presented in Supplementary Table 1. This systematic review has been registered on the PROSPERO platform: https://www.crd.york.ac.uk/prospero/#recordDetails.

**RESULTS**

A total of 57 studies were eligible and included in this review. They were from 11 countries, of which 33 (57.9%) were from China (Figure 2). Forty-two of the 57 studies reported abnormalities in liver enzymes[2,5,7-46], three mainly reported abnormalities in blood parameters[47-49], four indicated no significant liver function alterations[6,50-52], and another eight studies did not provide data on changes in liver function[53-60]. Fifty-seven studies were retrospective, and the total number of co-infections was 1932, the largest sample size was 7723[54], and the largest number of co-infections was 353[16]. Most of the studies suggested an interaction between hepatitis B and COVID-19, while 12 studies clearly indicated no interaction between hepatitis B and COVID-19[5,11,16,18,21,25,28,50,51,54-56]. Six of the 57 studies clearly reported HBV activation[23,29,41,43,46,52]. Six studies were related to liver transplant patients[36,38,39,49,57,58].

***Interpretation of ‘no effect’ results***

As previously mentioned, the possible reasons why HBV infection was not associated with clinical outcomes of COVID-19, despite the fact that some patients had high liver enzyme levels, are as follows: (1) The infection rate is not affected. The main consideration is the positive effect of nucleoside analogues on resistance to SARS-CoV-2[59]. In the included studies, some hepatitis B patients received long-term treatment with nucleoside analogues, such as tenofovir, which binds tightly to RNA-dependent RNA polymerase and terminates SARS-CoV-2 RNA synthesis[61,62], resulting in a low rate of SARS-CoV-2 infection in chronic hepatitis B (CHB) patients treated with anti-HBV drugs; (2) The severity of the disease is not affected. The main consideration is the key role played by immune dysfunction in SARS-CoV-2 and HBV co-infected patients. The cytokine storm caused by SARS-CoV-2 infection leads to overproduction of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-2, while HBV infection with persistent viral antigens leads to virus-specific CD4+ and CD8+ T cell depletion, resulting in impaired cytokine secretion, especially IL-2 and TNF-α, in which the depleted and immunosuppressed state of HBV-specific T lymphocytes may attenuate or avoid the excessive host immune response to SARS-CoV-2 and reduce the cytokine storm, resulting in a less severe disease[63-65]; and (3) Prognosis is not affected. Previous studies have demonstrated that hepatitis C virus infection can limit the replication of HBV[66], a phenomenon called viral interference, in which one virus in the host prevents the replication of another co-infected virus by competitive inhibition rather than by the action of immune antibodies. Impaired type I interferon activity has been found to be a major feature of patients with severe COVID-19[67-69]. When co-infected, HBV can inhibit the replication and proliferation of co-infected SARS-CoV-2 by enhancing type I interferon signaling, thereby reducing viral load and prolonging survival. In addition to this, the small number of HBV co-infected patients in the 57 studies that we included may have influenced the results.

***Interpretation of altered liver enzymes and other biochemical abnormalities***

**Explanation of enzyme system abnormalities:** Many studies have suggested that elevated liver enzyme systems are associated with drug therapy (Supplementary Table 1). Corticosteroids have been widely used to treat and benefit COVID-19[70]. Systemic corticosteroids are also associated with an increased risk of aspartate aminotransferase (AST) elevation[71]. Several studies have reported that elevated liver enzyme systems are associated with antiviral therapy medication[72-74]. The results of these studies showed that liver enzyme levels in patients dropped to near normal within a few days after discontinuation of medication. In addition, a study by Lei *et al*[71] showed that elevated AST and alkaline phosphatase levels were associated with the use of antifungal drugs. Another explanation is that some enzymes reflecting liver function, such as glutamic aminotransferase, are nonspecific and are expressed in a wide range of tissues, including heart, skeletal muscle, red blood cells, and liver, and can originate from other sites[75,76].

**Explanation for the decrease in albumin:** Patients with SARS-CoV-2 and HBV co-infection show a decrease in albumin, especially in heavy and critically ill patients, which may be due to the high catabolic state of the patient’s body, poor nutritional status, negative nitrogen balance, and insufficient raw materials for synthesizing albumin, as well as impaired hepatic synthesis of albumin due to hepatocyte damage. Corticosteroid treatment can also cause a decrease in albumin during the treatment process[21]. COVID-19 patients co-infected with HBV have lower prealbumin levels due to weaker hepatic reserve capacity, which also contributes to the decrease in albumin. With the resolution of the disease, most of the patients’ liver function will return to normal.

**Explanation for lymphocytopenia and thrombocytopenia:** Patients with SARS-CoV-2 and HBV co-infection have significantly lower white blood cell counts, mainly due to reduced lymphocyte counts and significantly lower monocyte levels. The mechanism leading to lymphocytopenia remains unclear. Since low lymphocyte counts are associated with increased disease severity and mortality in COVID-19[77,78], patients with SARS-CoV-2 and HBV co-infection may be in greater need of increased clinical surveillance. Thrombocytopenia is common in liver disease caused by HBV infection. The mechanism of thrombocytopenia in COVID-19 may be that SARS-CoV-2 reduces platelet production, increases platelet destruction, or increases platelet consumption[79]. Specifically, the lung is one of the organs where megakaryocytes dynamically release platelets[80], and SARS-CoV-2 damages the lungs of COVID-19 patients through angiotensin-converting enzyme 2 (ACE2), leading to increased destruction of megakaryocytes in the lung and resulting in decreased platelet production. In addition, SARS-CoV-2 may directly invade hematopoietic cells or infect bone marrow stromal cells by binding to CD13 or CD66a receptors, *etc.,* damaging megakaryocytes and platelets and exacerbating apoptosis[81]. Cytokine storm leads to immune hyperactivation, causing cellular damage and increased platelet destruction through autoantibody or immune complex activation of complement; at the same time, immune hyperactivation results in the release of large amounts of inflammatory factors that promote excessive platelet activation and platelet-monocyte aggregation formation[82], forming thrombi at the site of injury and further leading to increased platelet depletion and destruction.

**DISCUSSION**

***Impact of COVID-19 on hepatitis B***

We mainly describe the effects of COVID-19 on hepatitis B from the aspects of HBV reactivation, abnormal liver enzyme system, mortality, and liver histopathological changes.

**HBV reactivation:** Six of the 57 included studies reported COVID-19-induced HBV reactivation (Supplementary Table 1), which primarily refers to the re-detection of HBV DNA in patients who previously had HBV DNA below the lower limit of detection or a sudden and substantial increase in HBV DNA levels in individuals with detectable HBV DNA[83]. In some cases, it may also evolve into fulminant liver failure. The mechanism of HBV reactivation after SARS-CoV-2 infection is mainly due to a disruption of the balance between the immune status of the host and viral replication. The intensity of glucocorticoid or immunosuppressive therapy is a major risk factor for HBV reactivation during COVID-19 treatment[29,41,84]. Age, male sex, and severe comorbidities (such as hypertension, diabetes, hypercholesterolemia, and chronic kidney disease) are considered risk factors for HBV reactivation[29]. In addition, SARS-CoV-2 infection causes significant lymphopenia, which may increase the likelihood of HBV reactivation.

Although there is a risk of HBV reactivation with SARS-CoV-2 infection, studies have shown that the overall risk is low. In a study by Rodríguez-Tajes *et al*[29], 61 patients with severe COVID-19 on immunosuppressive therapy were followed up for at least one month and no cases of hepatitis B surface antigen (HBsAg) reversal were found, with only two (3%) patients having detectable serum HBV-DNA.

Considering the risk of reactivation, it is recommended that HBV patients should start or continue anti-HBV therapy once COVID-19 is diagnosed[85], and some scholars recommend treatment with the nucleoside analogs entecavir and tenofovir[83], and closely monitoring HBV virological indicators and indicators related to liver injury. It has been suggested that the use of IL-6 receptor antagonists can reduce the risk of HBV reactivation, and in Watanabe *et al*[86]’s study, 152 patients who recovered from HBV infection treated with disease-modifying antirheumatic drugs had a very low risk of HBV reactivation (< 5%).

**Abnormalities in liver enzymes:** Most studies have evaluated the effects of COVID-19 in HBV infected patients mainly manifesting as abnormalities in liver enzymes, dominated by elevated levels of alanine aminotransferase (ALT), AST, and total bilirubin (TBIL), especially in severely ill patients[2,5,7-46] (Supplementary Table 1). Several studies have shown a predominance of AST elevations in COVID-19 patients[14,17,71,87], reflecting the severity of the disease. A large study including 5700 subjects showed elevated levels of AST (58%) and ALT (39%) in hospitalized COVID-19 patients[17]. Sixty-two percent of critically ill patients had elevated AST levels[88]. Abnormal liver function tests ranged from 37% to 69%, ALT and AST increased by 18.2% to 31.6% and 14.8% to 35.4%, respectively[14,52,89,90], and several studies have reported elevated TBIL elevation (5.1% to 11.5%)[89,91]. It is worth noting that AST alone does not prove with certainty that more liver damage occurred, as other tissues, including heart or muscle tissue, can also release glutathione[75,76].

Zhao *et al*[92] also noted that COVID-19 patients had significantly higher levels of γ-glutamyl transpeptidase, lactate dehydrogenase (LDH), and α-hydroxybutyric dehydrogenase than non-COVID-19 patients. A study by Chen *et al*[27] including 113 deceased patients (five of whom were co-infected with SARS-CoV-2 and HBV) showed that the deceased patients had creatinine, creatine kinase (CK), LDH, cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), D-dimer, IL-2 receptor (IL2R), IL-6, IL-8, IL-10, and TNF-α concentrations that were significantly higher compared to those in recovered patients. Among these, several studies have confirmed that NT-proBNP is strongly and independently associated with mortality in COVID-19 patients[93-95]. In addition, serum albumin was below the normal range, and prothrombin time was prolonged due to the compromised synthetic function of the liver.

**Mortality:** Several reports have suggested that pre-existing liver disease may be associated with high mortality in patients with COVID-19[96-99]. Studies have noted that the risk of mortality is associated with pre-existing liver disease status and not with age, race, body mass index, hypertension, or diabetes[96]. Several studies have evaluated the relationship between the severity of abnormal liver tests and mortality in patients with COVID-19[1,14,96,97]. A study from the United States showed that among 2780 patients with COVID-19, the mortality rate was 12% in patients with chronic liver disease (10 out of 250 patients with chronic liver disease have CHB), compared to 4% in patients without liver disease[99]. Another study of 152 consecutively submitted COVID-19 cases in patients with chronic liver disease found a higher mortality rate in COVID-19 patients with combined chronic liver disease, 11.8% of whom were hepatitis B patients[96]. These studies support that SARS-CoV-2 affects the immune response, exacerbating HBV replication during the acute and chronic phases of hepatitis B infection[12]. Iavarone *et al*[45] also concluded that COVID-19 is associated with increased mortality in patients with deteriorating liver function. The cause of death may be related to the failure of patients to receive timely specialist care, inadequate hepatoprotective therapy, and hepatitis B infection complicated by SARS-CoV-2 leading to fulminant hepatitis and multi-organ failure.

**Histopathological changes of the liver:** Histopathology-specific manifestations of the liver in patients with COVID-19 include binucleated or multinucleated hepatocytes, swollen mitochondria, and reduced glycogen granules[47]. Macrovesicular steatosis is one of the common nonspecific manifestations[72], in addition to mild portal lymphocytic infiltration, mild sinusoidal dilatation, inflammatory cells in the sinusoids, and portal vein inflammation, with electron microscopy also showing the presence of viral particles[100-103].

***Effect of hepatitis B on COVID-19***

We will describe the effect of hepatitis B on COVID-19 in terms of the rate of infection in patients with hepatitis B, changes in biochemical indicators and cytokines, and the prognostic effect of hepatitis B on COVID-19 (including mortality, complications, and severe COVID-19).

**Rate of infection:** An important indicator of the impact of hepatitis B on COVID-19 is the rate of infection. It has been shown that hepatitis virus infection reduces the chance of COVID-19 infection to some extent in people with hepatitis B[15]. Antiviral drugs also reduce susceptibility to COVID-19 infection. Data from Naderi *et al*[15] showed that the risk of COVID-19 in healthy individuals was 2.3 times higher than that in patients with CHB. Antiviral therapy in patients with CHB, including tenofovir and entecavir, resulted in a decreased incidence of SARS-CoV-2 positivity. Kang *et al*[54]reported that the occurrence of CHB resulted in a lower rate of SARS-CoV-2 positivity. A recently published survey of a larger cohort in Spain showed a reduced incidence of COVID-19 infection in CHB patients given tenofovir, suggesting a positive effect of tenofovir on SARS-CoV-2[59]. A large study in the United States including 5700 inpatients with COVID-19 showed that 14% (13/93) of CHB patients and 32.25% (20/62) of controls were infected with SARS-CoV-2, respectively, and the risk of developing COVID-19 was 2.3 times higher in healthy controls than in CHB patients, suggesting that antiviral drugs also reduced the susceptibility to SARS-CoV-2 infection[17].

**Cytokines and biochemical indicators:** As with the effects of COVID-19 on hepatitis B, SARS-CoV-2 and HBV co-infection aggravates liver injury in COVID-19 patients[5,24], leading to abnormalities in the liver enzyme system. In addition to ALT, AST, alkaline phosphatase, and TBIL described previously[30,32,37], IL-6, LDH, D-dimer TNF-α, CK, and other inflammatory factors levels are elevated[14,27,104,105].

Among the cytokines in co-infected patients, IL-6 was most significantly elevated. IL-6 is the result of SARS-CoV-2 activation of the immune system leading to massive cytokine release[106]. IL-6 plays a role as a pro-inflammatory factor in the regulation of vascular leakage, complement activation, and coagulation pathways. The coagulation biomarker D-dimer is derived from the formation and cleavage of cross-linked fibrin, and the systemic pro-inflammatory cytokine response following viral infection may induce endothelial cell dysfunction, leading to overproduction of thrombin, which activates platelets and stimulates fibrinolysis, resulting in elevated D-dimer[107,108]. D-dimer has also been found in COVID-19 patients to be associated with poor outcome and abnormally dysregulated in CHB patients[109]. LDH not only plays an important role in glucose metabolism by catalyzing the conversion of pyruvate to lactate, but also regulates the immune response by inducing T cell activation and enhancing immunosuppressive cells through lactate production[110]. Serum CK levels are the most sensitive indicator of muscle damage[111]. Hypovolemia occurring in dehydrated patients with severe COVID-19 may lead to renal failure, which may increase CK levels[25]. Two recent studies suggest that high CK, IL-6, and D-dimer levels may be early warning indicators of serious disease and monitoring these indicators may help in the early detection of adverse events[25,112].

**Mortality, complications, or serious prognosis:** Patients with SARS-CoV-2 and HBV co-infection are more likely to have severe disease and a worse prognosis, including higher mortality and complications[44,55,60]. Two recent studies have shown that patients with COVID-19 who have pre-existing liver disease have a higher mortality rate compared to patients without liver disease[96,97]. Mirzaie *et al*[113] found that of the reported SARS-CoV-2-HBV co-infection cases, the mortality rate was 4.7%, 14.1% were transferred to the intensive care unit (ICU), and 38.8% reported severe COVID-19. In a study by Chen *et al*[9], seven of 15 HBV-infected patients (46.7%) developed severe disease, compared with 24.1% of severe cases in COVID-19 patients without HBV infection. In a study of 436 patients with COVID-19, more patients with CHB developed a severe status compared to non-CHB patients [30/109 (27.52% *vs* 5.20%) 17/327], with mortality rates of 13/109 (11.93%) and 8/327 (2.45%), respectively[8]. Another recent study by Wu *et al*[44] involving 70 co-infections showed a higher proportion of severe patients and critical patients in the COVID-19 and HBV co-infected group than in the non-HBV infected group (32.86% *vs* 15.27%). Data from a study by Yang *et al*[30] showed that patients with COVID-19 combined with CHB had a higher risk of death and ICU admission than patients without CHB. These data support the hypothesis that patients with liver disease may be associated with serious outcomes in patients with COVID-19. However, it is unclear whether these results reflect the severity of the patient’s pre-existing liver disease or the severe prognosis caused by SARS-CoV-2 itself. However, it has also been reported to the contrary, that is, the incidence of ICU admission or death may be lower in patients with observed pre-existing HBV infection [none (0%) *vs* 36 (6.47%)] compared to 556 of 571 COVID-19 cases without HBV infection[20]. These findings suggest that the immune status of the host is influenced to some extent by CHB, which may affect the consequences of infection by SARS-CoV-2.

***COVID-19 has no effect on hepatitis B***

Yu *et al*[6] included 7 HBsAg(+) and 60 HBsAg(-) (a total of 67) COVID-19 patients and found no extensive fluctuations in markers of HBV replication during the acute course of SARS-CoV-2 infection, indicating that SARS-CoV-2 had no effect on HBV kinetics, and that co-infection did not prolong viral shedding or latency cycles in COVID-19 patients, and it did not trigger reactivation or seroconversion of CHB. Therefore, they concluded that SARS-CoV-2 infection would not be a source of HBV reactivation. Ding *et al*[28] conducted a study in which 204 of 2073 patients with COVID-19 had pre-existing liver disease, including 134 patients with hepatitis B and five patients with CHB cirrhosis, and after adjusting for baseline characteristics by matching propensity scores between groups, the in-hospital mortality rate in patients with hepatitis B was similar to that in patients without liver disease. These results suggest that SARS-CoV-2 infection may not increase the risk of severe liver injury in patients with hepatitis B and in patients with compensated liver function.

***Hepatitis B has no effect on COVID-19***

In a study by Wen *et al*[21], patients with COVID-19 combined with hepatitis B had no significant increase in the probability of abnormal ALT, AST, and albumin compared to patients without combined hepatitis B. No differences were found in various adverse clinical outcomes in patients with CHB compared to HBsAg negative patients. Chen *et al*[5] divided 326 COVID-19 confirmed cases into 20 patients with co-infection with HBV and 306 patients without HBV infection for observation and found no significant differences in the levels of liver function parameters, discharge rates, length of stay, or mortality between the two groups. Similarly, a study by Yu *et al*[6] showed that co-infection with HBV did not increase the severity of COVID-19 or prolong the length of hospital stay. There was also no significant difference between the two groups in terms of disease recovery at discharge. Zou *et al*[7] and Zhang *et al*[22] showed that the proportion of organ damage in patients co-infected with HBV was not significantly different from that in patients infected with SARS-CoV-2 alone. Liu *et al*[23] matched 21 patients with COVID-19 and HBV co-infection to 51 patients with COVID-19 without HBV, and found that HBV did not prolong the shedding of SARS-CoV-2, nor did it add to the progression of COVID-19 or increase the risk of poor prognosis. Similarly, Li *et al*[18] and He *et al*[20] had similar conclusions. Hepatic biochemistry (ALT, AST, and TBIL) was similarly dynamic and insignificantly different between the two groups of patients at each time point. In addition, HBV antiviral therapy has been reported to have a limited impact on the incidence and outcome of COVID-19[114]. The analysis by Zhu *et al*[115] also supports the view that HBV is not a significant risk factor for serious adverse outcomes among hospitalized patients with COVID-19.

Data from several studies have shown that co-infection did not negatively affect the course of COVID-19, although the SARS-CoV-2/HBV co-infection group had higher results in terms of liver function index levels[16,25,28]. Guardigni *et al*[56] in a study of 606 subjects found no statistical difference in mortality between the two groups, despite the higher rate of admission to the ICU in HBV-positive individuals. Pre-existing viral liver infections had no impact on the clinical and virological evolution of COVID-19. A study by Liu *et al*[48] found that although patients co-infected with SARS-CoV-2 and HBV exhibited more severe monocytopenia, thrombocytopenia, and hepatic dysfunction in albumin production and lipid metabolism, no differences in inflammatory cytokine levels were observed between patients co-infected with SARS-CoV-2 and HBV and those infected with SARS-CoV-2 alone. Most of the disturbances could be reversed with recovery from COVID-19, and HBV co-infection had no significant effect on the outcome of COVID-19.

***Possible mechanisms of interaction between COVID-19 and liver injury***

The mechanisms underlying liver dysfunction in patients with SARS-CoV-2 and HBV co-infection are not fully understood and may include direct injury, immune injury, drug injury, ischemia and hypoxia, and reactivation of HBV with immunosuppressive drugs[8-11], or may be the result of a combination of factors.

**Direct injury:** SARS-CoV-2 replication directly causes liver damage. There is increasing evidence that SARS-CoV-2 can directly cause liver damage in patients with COVID-19. ACE2 is widely present in human organ tissues, with the highest expression in the small intestine and also in the spleen, brain, muscle, heart, and liver[116]. It has been shown that SARS-CoV-2 can use ACE2 as a receptor for cell entry[117,118]. Dipeptidyl peptidase 4 and transmembrane serine protease 2 can also act as receptors to mediate SARS-CoV-2 virus entry into host cells[119,120]. Pre-existing liver disease is associated with increased expression of ACE2 in hepatocytes, thereby increasing the likelihood of SARS-CoV-2 entry into hepatocytes[121,122]. Recent data have shown higher ACE2 expression in bile duct cells than in hepatocytes, suggesting that the virus may bind directly to ACE2 expressed on bile duct cells, leading to hepatic impairment[117,123]. These findings suggest that abnormal liver function may be caused by the preferential binding of SARS-CoV-2 to bile duct cells[124]. SARS-CoV-2 granules in the cytoplasm of COVID-19 patients’ hepatocytes, mitochondrial swelling and structural damage, and massive apoptosis of hepatocytes were shown by electron microscopy, strongly suggesting direct cytopathy of SARS-CoV-2 in hepatocytes[125,126].

**Immune impairment:** Currently, the most discussed immune injury is the ‘cytokine storm’. During the immune activation phase, the replication and proliferation of SARS-CoV-2 lead to cellular inflammatory necrosis and release of pro-inflammatory cytokines[127], activating T and B cells and recruiting macrophages[128-130], which in turn produce additional inflammatory factors, such as C-reactive protein, IL-6, IL-1, IL-8, and IL2R, leading to a cytokine storm that causes severe immune damage to the lung as well as the liver[131,132]. IL-6 is a potential risk factor for severe liver injury in patients with COVID-19[133,134]. IL-6 is produced *via* classical CIS-signaling or TRANS-signaling, two different pathways that lead to a systemic cytokine storm[135].

**Drug-induced liver injury:** The liver is an important organ for the metabolism of drugs, and antivirals are one of the main measures for the treatment of COVID-19. The drugs currently used for treatment, including antibacterial drugs, nonsteroidal anti-inflammatory drugs, traditional Chinese medicine, antiviral drugs, and other drugs used in clinical trials, such as chloroquine, hydroxychloroquine, and tocilizumab, may produce hepatotoxicity[72,96]. Cai *et al*[72] observed that lopinavir and ritonavir contributed significantly to liver injury in patients with COVID-19. Antifungal drugs and systemic corticosteroids have also shown a positive association with liver injury[71]. Traditional Chinese medicine plays a crucial role in the treatment of COVID-19, but it can also contribute to liver injury[136]. The mechanisms of liver injury are variable and it is generally believed that the pathogenesis of liver injury with antiviral drugs is related to mitochondrial toxicity, hypersensitivity/induced autoimmune hepatitis, and secondary bacterial infections[124,137]. In addition to this, HBV reactivation is also considered to be one of the manifestations of drug-induced liver injury, as HBV reactivation occurs at an increased rate in patients treated with high doses of long-term corticosteroids or immunomodulators[43].

***Ischemia and hypoxia of the liver***

Ischemia and hypoxia in the tissues and organs of COVID-19 patients after SARS-CoV-2 infection are common pathophysiological phenomena[78]. The consequences of progressive hypoxia may include viral proliferation, cytokine release, inflammation, and intravascular coagulation[78], leading to hypoxic injury in several organs, including the liver, and in severe cases, hypoxic hepatitis[138]. Cellular damage caused by hepatic ischemia and inflammatory response caused by reperfusion both lead to hepatocyte apoptosis and elevation of liver enzymes[139,140]. In addition, patients’ prior underlying diseases, such as chronic lung disease[91], diabetes[105], and gastrointestinal disease[141], have been predicted as possible mechanisms of liver injury in the context of viral infection. Interestingly, being male has also been reported to be associated with a high risk of liver injury[71,142].

***Drug treatment and alternative therapies***

COVID-19 combined with chronic liver disease has become a very prominent clinical problem, and the treatment and prevention of COVID-19 combined with liver injury are particularly important. In the treatment of COVID-19 combined with hepatitis B, the first priority is to treat the cause, followed by a comprehensive treatment plan of antiviral therapy, use of antibiotics, liver protection, and nutritional support, as well as aggressive treatment of comorbidities, such as hypertension and diabetes. Corticosteroids are now widely used to treat COVID-19, antiviral therapy is a basic treatment, and in China, traditional Chinese medicine is also used to treat SARS-CoV-2 infection[143]. Nucleoside (acid) analogues are used in the treatment of CHB. These drugs are effective in inhibiting HBV replication, reducing viral load, and improving liver histological lesions. Some studies have shown that in patients with SARS-CoV-2 and HBV co-infection, the use of nucleoside analogs is safe and does not lead to exacerbation of the disease due to drug administration. However, antiviral drugs may also cause liver damage, and corticosteroids may increase the risk of hepatitis exacerbation in patients with chronic HBV infection, especially when combined with other immunosuppressive drugs[144]. Therefore, the use of hepatoprotective drugs and close monitoring of changes in liver function are recommended in clinical work to minimize the risk of liver injury and HBV reactivation.

Interestingly, some authors have suggested that hemoperfusion can delay the progression of the hyperinflammatory process of COVID-19 and remove the toxins involved in acute liver failure, and could be an alternative option to mitigate disease progression in patients with COVID-19[26]. In addition, plasma therapy in recovering patients has been reported to be very effective in patients who still have the virus in their system[145,146].

***Care monitoring and social management***

During the COVID-19 pandemic, delays in the care of patients other than those with COVID-19 may result in negative outcomes for CHB patients due to discontinuation of antiviral therapy. Patients with hepatitis B, especially those in the decompensated phase of cirrhosis, many of whom have a decline in blood cells associated with hypersplenism, will frequently present with pulmonary and abdominal infections due to their reduced immune function, and this is a particularly important situation to screen and identify. For patients with HBV combined with SARS-CoV-2 infection, it is recommended not to discontinue anti-HBV drugs and to strengthen the dynamic monitoring of the patient’s liver function. The diagnosis and treatment of chronic diseases are long-term, and a variety of problems may still be faced in the post-pandemic era. Therefore, it is important to emphasize the importance of network hospitals, strengthen the use of network cloud platforms, increase network consultation and follow-up, provide online assistance to these patients, and reduce unnecessary hospital visits. It is also important to avoid large gatherings during a pandemic, and be careful to wear masks and wash your hands more often in public places.

***Vaccination***

The already licensed COVID-19 vaccine is immunogenic and has a good short-term safety record[147-151]. Given the potential for SARS-CoV-2 infection to have serious health consequences in patients with hepatitis B, patients with liver disease should be considered a priority population for receiving the vaccine. The potential interactions between the COVID-19 vaccine and other vaccines have not been well studied, and the few data available is limited to the concurrent use of the COVID-19 vaccine and influenza vaccine, with studies showing that antibody responses to both vaccines were maintained, and no safety issues were reported[137]. Future clinical studies on the interaction between the COVID-19 vaccine and hepatitis B vaccine are urgently needed.

***Limitations***

The present review has several limitations. First, most of the current research papers on SARS-CoV-2 and HBV co-infection were retrospectively designed, and no randomized controlled studies were found, which means that a selection bias must be acknowledged. Second, some studies do not distinguish the clinical stage of HBV infection and do not clarify the immune stage of the patient. Clinical outcomes may be different in patients with chronic HBV infection or acute HBV infection, and the prognosis of COVID-19 may be influenced by the status of the patient’s immune system, which may affect the interpretation of the results. Third, the results related to hepatitis B were derived from a limited sample size of observational and case studies, some of which were not classical studies on hepatitis B. The participation of patients with hepatitis B may have partially contributed to these studies, and thus the overall analysis may have overstated its role in COVID-19. Finally, because different countries have different institutions, policies, and economic conditions regarding COVID-19, and the 57 studies extracted for our review were distributed across 11 countries, it is necessary to carefully interpret whether there is regional or population bias in these results (Figure 2) and whether they are representative of the entire population.

**CONCLUSION**

In conclusion, both SARS-CoV-2 and HBV are globally pathogenic viruses, and there are currently few and conflicting data on the potential association between COVID-19 and hepatitis B. In the future, high-quality randomized trials are needed to further elucidate the interaction between COVID-19 and hepatitis B. To our knowledge, our review is the most comprehensive report to date describing the association between COVID-19 and hepatitis B. By reviewing these studies, we provide direct evidence of some association between COVID-19 and hepatitis B, explain the clinical phenomena that they exhibit, explore the possible mechanisms of the interaction between COVID-19 and hepatitis B, and provide management measures for co-infected patients, and therefore, our review can provide a reference for future scientific studies and clinical management.

**ARTICLE HIGHLIGHTS**

***Research background***

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis B virus (HBV) infections are two major current global public health crises. Both SARS-CoV-2 and HBV infections can cause liver damage. It is unclear whether HBV itself makes patients more susceptible to coronavirus disease 2019 (COVID-19), or whether COVID-19 leads to worse outcomes in patients with HBV infection. There are few and conflicting data on the association between COVID-19 and hepatitis B.

***Research motivation***

All current studies on patients with both COVID-19 and hepatitis B will be searched to explore the complex relationship between COVID-19 and hepatitis B in order to inform the research and management of patients co-infected with SARS-CoV-2 and HBV.

***Research objectives***

We searched almost all current clinical studies on COVID-19 combined with hepatitis B to describe their interaction, possible mechanisms, and clinical interventions to inform the clinical management of this special population with SARS-CoV-2 and HBV co-infection.

***Research methods***

We used an inclusive search strategy and searched the literature in the following online databases: PubMed, China National Knowledge Infrastructure, Google Scholar, Scopus, Wiley, Web of Science, Cochrane, and ScienceDirect, as well as medRxiv and bioRxiv, and also manually searched references of the included studies. Articles reporting studies conducted in humans and discussing hepatitis B and COVID-19 were included. We extracted the relevant data from the full text of eligible studies for the table after excluding duplicative publications. Some topics that included HBV or COVID-19 samples but did not have quantitative evidence were excluded from the review.

***Research results***

After excluding duplications and publications without quantitative evidence, a total of 57 studies were eligible and included in this review; all were retrospective, and they were from 11 countries. Most of the studies suggested an interaction between hepatitis B and COVID-19, mainly in the form of abnormal liver enzymes, abnormal blood parameters, and HBV reactivation; however, 12 of these studies clearly indicated no effect between hepatitis B and COVID-19.

***Research conclusions***

Both SARS-CoV-2 and HBV are both globally pathogenic viruses, and there are few and conflicting data on the potential association between COVID-19 and hepatitis B. Our review provides direct evidence for some associations between COVID-19 and hepatitis B, explains the clinical phenomena that they exhibit, explores the possible mechanisms of the interaction between COVID-19 and hepatitis B, and provides management measures for co-infected patients.

***Research perspectives***

To our knowledge, our review is the most comprehensive report to date describing the association between COVID-19 and hepatitis B. In the future, high-quality randomized trials are needed to further elucidate the interaction between COVID-19 and hepatitis B.

**REFERENCES**

1 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

2 **Zou XJ**, Wu L, Zhou W, Fang MH. Characteristics of liver function of patients with chronic hepatitis B and coronavirus disease. *J Mil Med Sci* 2020; **44**: 370-373

3 **Zhong ZF**, Huang J, Yang X, Peng JL, Zhang XY, Hu Y, Fu N, Lin HL, Jiang B, Tian YY, Yao HY, Deng LP, Tang XQ, Zhou JC, Tang J, Xie X, Liu Q, Liu J, Dou CY, Dai RJ, Yan B, Yang XF. Epidemiological and clinical characteristics of COVID-19 patients in Hengyang, Hunan Province, China. *World J Clin Cases* 2020; **8**: 2554-2565 [PMID: 32607332 DOI: 10.12998/wjcc.v8.i12.2554]

4 **Xia Y**, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. *Gastroenterology* 2019; **156**: 311-324 [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057]

5 **Chen L**, Huang S, Yang J, Cheng X, Shang Z, Lu H, Cheng J. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. *J Viral Hepat* 2020; **27**: 1504-1507 [PMID: 32668494 DOI: 10.1111/jvh.13362]

6 **Yu R**, Tan S, Dan Y, Lu Y, Zhang J, Tan Z, He X, Xiang X, Zhou Y, Guo Y, Deng G, Chen Y, Tan W. Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection. *Virology* 2021; **553**: 131-134 [PMID: 33276282 DOI: 10.1016/j.virol.2020.11.012]

7 **Zou X**, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. *Clin Gastroenterol Hepatol* 2021; **19**: 597-603 [PMID: 32553907 DOI: 10.1016/j.cgh.2020.06.017]

8 **Wang J**, Lu Z, Jin M, Wang Y, Tian K, Xiao J, Cai Y, Wang Y, Zhang X, Chen T, Yao Z, Yang C, Deng R, Zhong Q, Deng X, Chen X, Yang XP, Wei G, Wang Z, Tian J, Chen XP. Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study. *Front Med* 2022; **16**: 111-125 [PMID: 34387851 DOI: 10.1007/s11684-021-0854-5]

9 **Chen X**, Jiang Q, Ma Z, Ling J, Hu W, Cao Q, Mo P, Yao L, Yang R, Gao S, Gui X, Hou W, Xiong Y, Li J, Zhang Y. Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection. *Virol Sin* 2020; **35**: 842-845 [PMID: 32839868 DOI: 10.1007/s12250-020-00276-5]

10 **Qi X**, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. *Hepatol Int* 2020; **14**: 478-482 [PMID: 32440857 DOI: 10.1007/s12072-020-10051-z]

11 **Hambali NL**, Mohd Noh M, Paramasivam S, Chua TH, Hayati F, Payus AO, Tee TY, Rosli KT, Abd Rachman Isnadi MF, Manin BO. A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level. *Front Public Health* 2020; **8**: 584552 [PMID: 33304877 DOI: 10.3389/fpubh.2020.584552]

12 **Ali E**, Ziglam H, Kohla S, Ahmed M, Yassin M. A Case of Fulminant Liver Failure in a 24-Year-Old Man with Coinfection with Hepatitis B Virus and SARS-CoV-2. *Am J Case Rep* 2020; **21**: e925932 [PMID: 33046686 DOI: 10.12659/AJCR.925932]

13 **Zha L**, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust* 2020; **212**: 416-420 [PMID: 32266987 DOI: 10.5694/mja2.50577]

14 **Cai Q**, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020; **75**: 1742-1752 [PMID: 32239761 DOI: 10.1111/all.14309]

15 **Naderi M**, Hosseini S, Behnampour N, Shahramian I, Moradi A. Impact of COVID-19 in Chronic Viral Hepatitis B Patients on Virological, Clinical, and Paraclinical Aspects. *Jundishapur J Microb* 2022 [DOI: 10.5812/jjm-127312]

16 **Yip TC**, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. *Hepatology* 2021; **74**: 1750-1765 [PMID: 33961298 DOI: 10.1002/hep.31890]

17 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]

18 **Li Y**, Li C, Wang J, Zhu C, Zhu L, Ji F, Liu L, Xu T, Zhang B, Xue L, Yan X, Huang R, Wu C, Yan X. A case series of COVID-19 patients with chronic hepatitis B virus infection. *J Med Virol* 2020; **92**: 2785-2791 [PMID: 32558945 DOI: 10.1002/jmv.26201]

19 **Bongiovanni M**, Zago T. Acute hepatitis caused by asymptomatic COVID-19 infection. *J Infect* 2021; **82**: e25-e26 [PMID: 32891635 DOI: 10.1016/j.jinf.2020.09.001]

20 **He Q**, Zhang G, Gu Y, Wang J, Tang Q, Jiang Z, Shao C, Zhang H, Chen Z, Ma B, Liu D, Xie G, Xu D, Huang Y, Zhang H, Liang M, Huang H, Wang Y, Liu H, Yang J, Pan H, Zou S, Li F, Wang F, Liu C, Wang W, Xiong B, Li X, Liu L, Yang J, Qi X. Clinical Characteristics of COVID-19 Patients With Pre-existing Hepatitis B Virus Infection: A Multicenter Report. *Am J Gastroenterol* 2021; **116**: 420-421 [PMID: 32925195 DOI: 10.14309/ajg.0000000000000924]

21 **Wen M**, Lu J, Xie Y. Clinical characteristics of coronavirus disease 2019 patients complicated with liver injury. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2020; **45**: 555-559 [PMID: 32879106 DOI: 10.11817/j.issn.1672-7347.2020.200225]

22 **Zhang B**, Huang W, Zhang S. Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients With Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol* 2020; **18**: 2633-2637 [PMID: 32553905 DOI: 10.1016/j.cgh.2020.06.011]

23 **Liu J**, Wang T, Cai Q, Sun L, Huang D, Zhou G, He Q, Wang FS, Liu L, Chen J. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. *Hepatol Res* 2020; **50**: 1211-1221 [PMID: 32761993 DOI: 10.1111/hepr.13553]

24 **Lin Y**, Yuan J, Long Q, Hu J, Deng H, Zhao Z, Chen J, Lu M, Huang A. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. *Genes Dis* 2021; **8**: 484-492 [PMID: 33225036 DOI: 10.1016/j.gendis.2020.11.005]

25 **Bekçibaşı M**, Arslan E. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) /Hepatitis B virus (HBV) Co-infected Patients: A case series and review of the literature. *Int J Clin Pract* 2021; **75**: e14412 [PMID: 34051031 DOI: 10.1111/ijcp.14412]

26 **Colaneri M**, Valsecchi P, Perotti L, Ludovisi S, Seminari E, Pieri TC, Sacchi P, Bruno R. Running out of bullets: The challenging management of acute hepatitis and SARS-COV-2 from the SMatteo COvid19 Registry (SMACORE). *Liver Int* 2020; **40**: 2655-2659 [PMID: 32679617 DOI: 10.1111/liv.14609]

27 **Chen T**, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; **368**: m1091 [PMID: 32217556 DOI: 10.1136/bmj.m1091]

28 **Ding ZY**, Li GX, Chen L, Shu C, Song J, Wang W, Wang YW, Chen Q, Jin GN, Liu TT, Liang JN, Zhu P, Zhu W, Li Y, Zhang BH, Feng H, Zhang WG, Yin ZY, Yu WK, Yang Y, Zhang HQ, Tang ZP, Wang H, Hu JB, Liu JH, Yin P, Chen XP, Zhang B; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. *J Hepatol* 2021; **74**: 1295-1302 [PMID: 33347952 DOI: 10.1016/j.jhep.2020.12.012]

29 **Rodríguez-Tajes S**, Miralpeix A, Costa J, López-Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. *J Viral Hepat* 2021; **28**: 89-94 [PMID: 32969557 DOI: 10.1111/jvh.13410]

30 **Yang S**, Wang S, Du M, Liu M, Liu Y, He Y. Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis. *Infect Dis Ther* 2022; **11**: 1229-1242 [PMID: 35471766 DOI: 10.1007/s40121-022-00638-4]

31 **Yigit Y**, Haddad M, Elmoheen A, Shogaa MR, Tawel R, Mohamed YK, Salem W, Fawzy Eltawagny M. Can COVID-19 Cause Flare-Ups of Acute Hepatitis B? An Atypical Presentation of COVID-19 with Acute Hepatitis B. *Case Rep Infect Dis* 2021; **2021**: 8818678 [PMID: 33564481 DOI: 10.1155/2021/8818678]

32 **Aldhaleei WA**, Alnuaimi A, Bhagavathula AS. COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates. *Cureus* 2020; **12**: e8645 [PMID: 32550096 DOI: 10.7759/cureus.8645]

33 **Ji D**, Zhang D, Yang T, Mu J, Zhao P, Xu J, Li C, Cheng G, Wang Y, Chen Z, Qin E, Lau G. Effect of COVID-19 on patients with compensated chronic liver diseases. *Hepatol Int* 2020; **14**: 701-710 [PMID: 32734407 DOI: 10.1007/s12072-020-10058-6]

34 **Kim D**, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. *Clin Gastroenterol Hepatol* 2021; **19**: 1469-1479.e19 [PMID: 32950749 DOI: 10.1016/j.cgh.2020.09.027]

35 **Wang H**, Liu Y, Gao XL, Lei XY. Severe Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection: a case report and literature review. *J Community Med* 2021; **19**: 588-590

36 **Zhong Z**, Zhang Q, Xia H, Wang A, Liang W, Zhou W, Zhou L, Liu X, Rao L, Li Z, Peng Z, Mo P, Xiong Y, Ye S, Wang Y, Ye Q. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. *Am J Transplant* 2020; **20**: 1916-1921 [PMID: 32282986 DOI: 10.1111/ajt.15928]

37 **Huang JF**, Zheng KI, George J, Gao HN, Wei RN, Yan HD, Zheng MH. Fatal outcome in a liver transplant recipient with COVID-19. *Am J Transplant* 2020; **20**: 1907-1910 [PMID: 32277591 DOI: 10.1111/ajt.15909]

38 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020; **72**: 1491-1493 [PMID: 32220017 DOI: 10.1002/hep.31257]

39 **Loinaz C**, Marcacuzco A, Fernández-Ruiz M, Caso O, Cambra F, San Juan R, Justo I, Calvo J, García-Sesma A, Manrique A, Pérez-Jacoiste Asín MA, Folgueira MD, Aguado JM, Lumbreras C. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. *Transpl Infect Dis* 2020; **22**: e13372 [PMID: 32562561 DOI: 10.1111/tid.13372]

40 **Adali G**, Gokcen P, Guzelbulut F, Gokcen Degirmenci Salturk A, Bugra Agaoglu N, Unal B, Doganay L, Ozdil K. Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection? *Hepatol Forum* 2021; **2**: 91-96 [PMID: 35784904 DOI: 10.14744/hf.2021.2021.0027]

41 **Sagnelli C**, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, Sagnelli E, Coppola N. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. *Pathogens* 2022; **11** [PMID: 35890060 DOI: 10.3390/pathogens11070816]

42 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

43 **Wu YF**, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, Shi YJ, Li XP. COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report. *World J Clin Cases* 2021; **9**: 5266-5269 [PMID: 34307577 DOI: 10.12998/wjcc.v9.i19.5266]

44 **Wu J**, Yu J, Shi X, Li W, Song S, Zhao L, Zhao X, Liu J, Wang D, Liu C, Huang B, Meng Y, Jiang B, Deng Y, Cao H, Li L. Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. *J Viral Hepat* 2021; **28**: 80-88 [PMID: 32929826 DOI: 10.1111/jvh.13404]

45 **Iavarone M**, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020; **73**: 1063-1071 [PMID: 32526252 DOI: 10.1016/j.jhep.2020.06.001]

46 **Huang SP**, Xu CT, Liu M, Shang ZY, Lu HZ. A case of HBV reactivation induced by novel coronavirus pneumonia. *Chinese Hepatology* 2020; **25**: 467-468

47 **Song SH**, Chen TL, Deng LP, Zhang YX, Mo PZ, Gao SC, Hu WJ, Xiong Y, Ma ZY. Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China. *Infect Dis Poverty* 2020; **9**: 82 [PMID: 32616030 DOI: 10.1186/s40249-020-00707-1]

48 **Liu R**, Zhao L, Cheng X, Han H, Li C, Li D, Liu A, Gao G, Zhou F, Liu F, Jiang Y, Zhu C, Xia Y. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. *Liver Int* 2021; **41**: 720-730 [PMID: 33351265 DOI: 10.1111/liv.14774]

49 **Fernández-Ruiz M**, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant* 2020; **20**: 1849-1858 [PMID: 32301155 DOI: 10.1111/ajt.15929]

50 **Ma GG**, Shen YX, Wu L, Luo Z, Zhu CW, Chen SY, Yu KH, Li F. Effect of liver injury on prognosis and treatment of hospitalized patients with COVID-19 pneumonia. *Ann Transl Med* 2021; **9**: 10 [PMID: 33553303 DOI: 10.21037/atm-20-4850]

51 **Parlar Y**, Keskin O, Kirmizigul B, Gencdal G, Zeybel M, Gumussoy M, Idilman R, Yurdaydin C. The course of COVID-19 infection in patients with chronic hepatitis B and Delta. *J Hepatol* 2022; **77**: S293 [DOI:10.1016/s0168-8278(22)00953-9]

52 **Li L**, Li S, Xu MM, Yu PF, Zheng SJ, Duan ZP, Liu J, Chen Y, Li JF. Risk factors related to hepatic injury in patients with corona virus disease 2019. 2020 Preprint. Available from: medRxiv:2020.02.28.20028514 [DOI: 10.1101/2020.02.28.20028514]

53 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

54 **Kang SH**, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. *PLoS One* 2021; **16**: e0258229 [PMID: 34610052 DOI: 10.1371/journal.pone.0258229]

55 **Oruç Z**, Ebinç S, Kalkan Z, Kaplan M, Küçüköner M, Urakçı Z, Oruç İ, Işıkdoğan A. COVID-19 infection in cancer patients: the effect of Hepatitis B immunization.*Med Res J* 2022;**6**:86-93 [DOI:10.5603/MRJ.a2021.0018]

56 **Guardigni V**, Rosselli Del Turco E, Badia L, Galli S, Scolz K, Viale P, Verucchi G. Pre-Existing HBV and HCV Infections Do Not Affect COVID-19-Related Outcomes: An Observational Retrospective Study. *Hepat Mon* 2021 [DOI:10.5812/hepatmon.116986]

57 **Patrono D**, Lupo F, Canta F, Mazza E, Mirabella S, Corcione S, Tandoi F, De Rosa FG, Romagnoli R. Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy. *Transpl Infect Dis* 2020; **22**: e13353 [PMID: 32500942 DOI: 10.1111/tid.13353]

58 **Liu B**, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. *Am J Transplant* 2020; **20**: 1891-1895 [PMID: 32243673 DOI: 10.1111/ajt.15901]

59 **Lens S**, Miquel M, Mateos-Muñoz B, García-Samaniego J, Forns X. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. *J Hepatol* 2020; **73**: 1262-1263 [PMID: 32673740 DOI: 10.1016/j.jhep.2020.07.007]

60 **Marjot T**, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. *J Hepatol* 2021; **74**: 567-577 [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024]

61 **Jockusch S**, Tao C, Li X, Anderson TK, Chien M, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. *Antiviral Res* 2020; **180**: 104857 [PMID: 32562705 DOI: 10.1016/j.antiviral.2020.104857]

62 **Elfiky AA**. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sci* 2020; **253**: 117592 [PMID: 32222463 DOI: 10.1016/j.lfs.2020.117592]

63 **Rehermann B**. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. *Nat Med* 2013; **19**: 859-868 [PMID: 23836236 DOI: 10.1038/nm.3251]

64 **Anugwom CM**, Aby ES, Debes JD. Inverse Association Between Chronic Hepatitis B Infection and Coronavirus Disease 2019 (COVID-19): Immune Exhaustion or Coincidence? *Clin Infect Dis* 2021; **72**: 180-182 [PMID: 32502247 DOI: 10.1093/cid/ciaa592]

65 **Brooks DG**, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. *J Virol* 2005; **79**: 10514-10527 [PMID: 16051844 DOI: 10.1128/JVI.79.16.10514-10527.2005]

66 **Li N**, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A Comprehensive Review. *Front Immunol* 2019; **10**: 1551 [PMID: 31333675 DOI: 10.3389/fimmu.2019.01551]

67 **Hadjadj J**, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, Pène F, Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kernéis S, Terrier B. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 2020; **369**: 718-724 [PMID: 32661059 DOI: 10.1126/science.abc6027]

68 **Bastard P**, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 2020; **370** [PMID: 32972996 DOI: 10.1126/science.abd4585]

69 **Zhang Q**, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner JD, Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli MJ, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton RP, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020; **370** [PMID: 32972995 DOI: 10.1126/science.abd4570]

70 **World Health Organization**. Corticosteroids for COVID-19. [cited 11 August 2022]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1

71 **Lei F**, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; **72**: 389-398 [PMID: 32359177 DOI: 10.1002/hep.31301]

72 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

73 **Weber S**, Mayerle J, Irlbeck M, Gerbes AL. Severe liver failure during SARS-CoV-2 infection. *Gut* 2020; **69**: 1365-1367 [PMID: 32327526 DOI: 10.1136/gutjnl-2020-321350]

74 **Falcão MB**, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19. *Am J Trop Med Hyg* 2020; **102**: 1214-1216 [PMID: 32314698 DOI: 10.4269/ajtmh.20-0276]

75 **Malakouti M**, Kataria A, Ali SK, Schenker S. Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do? *J Clin Transl Hepatol* 2017; **5**: 394-403 [PMID: 29226106 DOI: 10.14218/JCTH.2017.00027]

76 **Oh RC**, Hustead TR, Ali SM, Pantsari MW. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. *Am Fam Physician* 2017; **96**:709-715 [PMID: 29431403]

77 **Zhang N**, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. *Cell Res* 2005; **15**: 749-769 [PMID: 16246265 DOI: 10.1038/sj.cr.7290345]

78 **Yang X**, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**: 475-481 [PMID: 32105632 DOI: 10.1016/S2213-2600(20)30079-5]

79 **Xu P**, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. *Ann Hematol* 2020; **99**: 1205-1208 [PMID: 32296910 DOI: 10.1007/s00277-020-04019-0]

80 **Lefrançais E**, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* 2017; **544**: 105-109 [PMID: 28329764 DOI: 10.1038/nature21706]

81 **Amgalan A**, Othman M. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. *J Thromb Haemost* 2020; **18**: 1514-1516 [PMID: 32278338 DOI: 10.1111/jth.14832]

82 **Hottz ED**, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, Righy C, Franco S, Souza TML, Kurtz P, Bozza FA, Bozza PT. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood* 2020; **136**: 1330-1341 [PMID: 32678428 DOI: 10.1182/blood.2020007252]

83 **Loomba R**, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. *Gastroenterology* 2017; **152**: 1297-1309 [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009]

84 **Shi Y**, Zheng M. Hepatitis B virus persistence and reactivation. *BMJ* 2020; **370**: m2200 [PMID: 32873599 DOI: 10.1136/bmj.m2200]

85 **Reddy KR**. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. *Clin Liver Dis (Hoboken)* 2020; **15**: 191-194 [PMID: 32489654 DOI: 10.1002/cld.970]

86 **Watanabe T**, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. *Int J Rheum Dis* 2019; **22**: 574-582 [PMID: 30338649 DOI: 10.1111/1756-185X.13401]

87 **Feng G**, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Poucke SV, Liu WY, Zheng MH. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. *J Clin Transl Hepatol* 2020; **8**: 18-24 [PMID: 32274342 DOI: 10.14218/JCTH.2020.00018]

88 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

89 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]

90 **Bloom PP**, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, Schaefer E, Chung RT. Liver Biochemistries in Hospitalized Patients With COVID-19. *Hepatology* 2021; **73**: 890-900 [PMID: 32415860 DOI: 10.1002/hep.31326]

91 **Xie H**, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* 2020; **40**: 1321-1326 [PMID: 32239591 DOI: 10.1111/liv.14449]

92 **Zhao D**, Yao F, Wang L, Zheng L, Gao Y, Ye J, Guo F, Zhao H, Gao R. A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias. *Clin Infect Dis* 2020; **71**: 756-761 [PMID: 32161968 DOI: 10.1093/cid/ciaa247]

93 **Caro-Codón J**, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejon-Castrejon S, Rodriguez-Sotelo L, Martinez LA, Marco I, Merino C, Martin-Polo L, Garcia-Veas JM, Martinez-Cossiani M, Gonzalez-Valle L, Herrero A, López-de-Sa E, Merino JL; CARD-COVID Investigators. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail* 2021; **23**: 456-464 [PMID: 33421281 DOI: 10.1002/ejhf.2095]

94 **Belarte-Tornero LC**, Valdivielso-Moré S, Vicente Elcano M, Solé-González E, Ruíz-Bustillo S, Calvo-Fernández A, Subinara I, Cabero P, Soler C, Cubero-Gallego H, Vaquerizo B, Farré N. Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection. *J Clin Med* 2021; **10** [PMID: 33477268 DOI: 10.3390/jcm10020323]

95 **Weng H**, Yang F, Zhang L, Jin H, Liu S, Fan F, Liu Z, Zheng X, Yang H, Li Y, Yi T, Li H, Zhang Y, Li J. Joint Predictive Value of cTnI and NT-proBNP on Mortality in Patients with Coronavirus Disease 2019: A Retrospective Research in Wuhan, China. *J Transl Int Med* 2021; **9**: 177-184 [PMID: 34900628 DOI: 10.2478/jtim-2021-0034]

96 **Moon AM**, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. *J Hepatol* 2020; **73**: 705-708 [PMID: 32446714 DOI: 10.1016/j.jhep.2020.05.013]

97 **Singh S**, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology* 2020; **159**: 768-771.e3 [PMID: 32376408 DOI: 10.1053/j.gastro.2020.04.064]

98 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044]

99 **The OpenSAFELY Collaborative**, Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong A, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans S, Smeeth L, Goldacre, B. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 2020 Preprint. Available from: medRxiv:2020.05.06.20092999 [DOI: 10.1101/2020.05.06.20092999]

100 **Wang Y**, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol* 2020; **73**: 807-816 [PMID: 32437830 DOI: 10.1016/j.jhep.2020.05.002]

101 **Zhang Y**, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int* 2020; **40**: 2095-2103 [PMID: 32239796 DOI: 10.1111/liv.14455]

102 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

103 **Tian S**, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* 2020; **33**: 1007-1014 [PMID: 32291399 DOI: 10.1038/s41379-020-0536-x]

104 **Zhang L**, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost* 2020; **18**: 1324-1329 [PMID: 32306492 DOI: 10.1111/jth.14859]

105 **Fu L**, Fei J, Xu S, Xiang HX, Xiang Y, Tan ZX, Li MD, Liu FF, Li Y, Han MF, Li XY, Zhao H, Xu DX. Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective case-cohort study. 2020 Preprint. Available from: medRxiv:2020.04.02.20050997 [DOI: 10.1101/2020.04.02.20050997]

106 **Patra T**, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, Pinto AK, Ray RB, Ray R. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. *PLoS Pathog* 2020; **16**: e1009128 [PMID: 33284859 DOI: 10.1371/journal.ppat.1009128]

107 **Chen Z**, Xu W, Ma W, Shi X, Li S, Hao M, Fang Y, Zhang L. Clinical laboratory evaluation of COVID-19. *Clin Chim Acta* 2021; **519**: 172-182 [PMID: 33939954 DOI: 10.1016/j.cca.2021.04.022]

108 **Connors JM**, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020; **135**: 2033-2040 [PMID: 32339221 DOI: 10.1182/blood.2020006000]

109 **Qi T**, Zhu C, Lu G, Hao J, He Q, Chen Y, Zhou F, Chen J, Hou J. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study. *BMC Gastroenterol* 2019; **19**: 20 [PMID: 30704397 DOI: 10.1186/s12876-019-0941-0]

110 **Ding J**, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. *Cancer Biomark* 2017; **19**: 353-363 [PMID: 28582845 DOI: 10.3233/CBM-160336]

111 **Chen G**, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**: 2620-2629 [PMID: 32217835 DOI: 10.1172/JCI137244]

112 **Wang Y**, Hu Z, Luo J, Zhang F, Huang L, Li H, Wen X, Pan Y, Chen M, Ying R, Jiang H, Chen S, Pan Z, Chen H, Xu H, Lei C, Han Y. Clinical Characteristics and Abnormal Parameters Evolution in Patients With Novel Coronavirus Infection: A Case Series of 272 Cases in Guangzhou. *Disaster Med Public Health Prep* 2021: 1-7 [PMID: 34002684 DOI: 10.1017/dmp.2021.149]

113 **Mirzaie H**, Vahidi M, Shokoohi M, Darvishian M, Sharifi H, Sharafi H, Karamouzian M. COVID-19 among patients with hepatitis b or hepatitis C: A systematic review. 2020 Preprint. Available from: medRxiv:2020.10.22.20216317 [DOI: 10.1101/2020.10.22.20216317]

114 **Yousefifard M**, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, Safari S. Antiviral therapy in management of COVID-19: a systematic review on current evidence. *Arch Acad Emerg Med* 2020; **8**: e45 [PMID: 32309809]

115 **Zhu JH**, Peltekian KM. HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis. *Can Liver J* 2021; **4**: 16-22 [PMID: 35991468 DOI: 10.3138/canlivj-2020-0029]

116 **Han T**, Kang J, Li G, Ge J, Gu J. Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study. *Ann Transl Med* 2020; **8**: 1077 [PMID: 33145296 DOI: 10.21037/atm-20-4281]

117 **Chai X**, Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J, Lan F. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. 2020 Preprint. Available from: bioRxiv:2020.02.03.931766v1 [DOI: 10.1101/2020.02.03.931766v1]

118 **Zhou P**, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270-273 [PMID: 32015507 DOI: 10.1038/s41586-020-2012-7]

119 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280.e8 [PMID: 32142651 DOI: 10.1016/j.cell.2020.02.052]

120 **Strollo R**, Pozzilli P. DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19? *Diabetes Metab Res Rev* 2020; **36**: e3330 [PMID: 32336007 DOI: 10.1002/dmrr.3330]

121 **Meijnikman AS**, Bruin S, Groen AK, Nieuwdorp M, Herrema H. Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD. *J Hepatol* 2021; **74**: 748-749 [PMID: 33338513 DOI: 10.1016/j.jhep.2020.12.007]

122 **Paizis G**, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. *Gut* 2005; **54**: 1790-1796 [PMID: 16166274 DOI: 10.1136/gut.2004.062398]

123 **Banales JM**, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 269-281 [PMID: 30850822 DOI: 10.1038/s41575-019-0125-y]

124 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020; **40**: 998-1004 [PMID: 32170806 DOI: 10.1111/liv.14435]

125 **Elghannam MT**, Hassanien MH, Ameen YA, ELattar GM, ELRay AA, Turky EA, ELTalkawy MD. COVID-19 and liver diseases. *Egypt Liver J* 2022; **12**: 43 [PMID: 35880136 DOI: 10.1186/s43066-022-00202-2]

126 **Bangash MN**, Patel JM, Parekh D, Murphy N, Brown RM, Elsharkawy AM, Mehta G, Armstrong MJ, Neil D. SARS-CoV-2: Is the liver merely a bystander to severe disease? *J Hepatol* 2020; **73**: 995-996 [PMID: 32502510 DOI: 10.1016/j.jhep.2020.05.035]

127 **Merad M**, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol* 2020; **20**: 355-362 [PMID: 32376901 DOI: 10.1038/s41577-020-0331-4]

128 **Shimizu Y**. Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. *World J Clin Cases* 2020; **8**: 5835-5843 [PMID: 33344582 DOI: 10.12998/wjcc.v8.i23.5835]

129 **Rasouli J**, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K, Mari ER, Safavi F, Leist TP, Zhang GX, Rostami A. Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy. *J Immunol* 2015; **194**: 5085-5093 [PMID: 25917097 DOI: 10.4049/jimmunol.1403243]

130 **Moore JB**, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020; **368**: 473-474 [PMID: 32303591 DOI: 10.1126/science.abb8925]

131 **Crayne CB**, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. *Front Immunol* 2019; **10**: 119 [PMID: 30774631 DOI: 10.3389/fimmu.2019.00119]

132 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

133 **Zhan K**, Liao S, Li J, Bai Y, Lv L, Yu K, Qiu L, Li C, Yuan G, Zhang A, Mei Z. Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation. *Gut* 2021; **70**: 628-629 [PMID: 32571973 DOI: 10.1136/gutjnl-2020-321913]

134 **Eljilany I**, Elzouki AN. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. *Vasc Health Risk Manag* 2020; **16**: 455-462 [PMID: 33223833 DOI: 10.2147/VHRM.S280962]

135 **Hunter CA**, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol* 2015; **16**: 448-457 [PMID: 25898198 DOI: 10.1038/ni.3153]

136 **Ali N**. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *J Med Virol* 2020; **92**: 2409-2411 [PMID: 32516845 DOI: 10.1002/jmv.26097]

137 **Adams DH**, Hubscher SG. Systemic viral infections and collateral damage in the liver. *Am J Pathol* 2006; **168**: 1057-1059 [PMID: 16565481 DOI: 10.2353/ajpath.2006.051296]

138 **Zhao XY**, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, Yang AY, Yu BP, Huang ZP. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis* 2020; **20**: 311 [PMID: 32345226 DOI: 10.1186/s12879-020-05010-w]

139 **Peralta C**, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. *J Hepatol* 2013; **59**: 1094-1106 [PMID: 23811302 DOI: 10.1016/j.jhep.2013.06.017]

140 **Zhai Y**, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation--from bench to bedside. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 79-89 [PMID: 23229329 DOI: 10.1038/nrgastro.2012.225]

141 **Jin X**, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, Yu GD, Xu KJ, Wang XY, Gu JQ, Zhang SY, Ye CY, Jin CL, Lu YF, Yu X, Yu XP, Huang JR, Xu KL, Ni Q, Yu CB, Zhu B, Li YT, Liu J, Zhao H, Zhang X, Yu L, Guo YZ, Su JW, Tao JJ, Lang GJ, Wu XX, Wu WR, Qv TT, Xiang DR, Yi P, Shi D, Chen Y, Ren Y, Qiu YQ, Li LJ, Sheng J, Yang Y. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* 2020; **69**: 1002-1009 [PMID: 32213556 DOI: 10.1136/gutjnl-2020-320926]

142 **Hajifathalian K**, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, Sharaiha RZ; WCM-GI research group∗. Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications. *Gastroenterology* 2020; **159**: 1137-1140.e2 [PMID: 32389667 DOI: 10.1053/j.gastro.2020.05.010]

143 Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. [cited 11 August 2022]. Available online: http://www.nhc.gov.cn/jkj/s3577/202009/318683cbfaee4191aee29cd774b19d8d/files/f9ea38ce2c2d4352bf61ab0feada439f.pdf

144 **Hatano M**, Mimura T, Shimada A, Noda M, Katayama S. Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency. *Endocrinol Diabetes Metab* 2019; **2**: e00071 [PMID: 31294085 DOI: 10.1002/edm2.71]

145 **Gul MH**, Htun ZM, Shaukat N, Imran M, Khan A. Potential specific therapies in COVID-19. *Ther Adv Respir Dis* 2020; **14**: 1753466620926853 [PMID: 32436445 DOI: 10.1177/1753466620926853]

146 **Perotti C**, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, Franchini M, Covid-Plasma Task Force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. *Haematologica* 2020; **105**: 2834-2840 [PMID: 33256382 DOI: 10.3324/haematol.2020.261784]

147 **Alrashdan MS**, El-Kishawi M, Al Kawas S. The Co-Administration of COVID-19 and Hepatitis B Vaccines, Should Safety Be a Concern? *Infect Chemother* 2022; **54**: 542-544 [PMID: 35920274 DOI: 10.3947/ic.2022.0042]

148 **Meo SA**, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. *Eur Rev Med Pharmacol Sci* 2021; **25**: 1663-1669 [PMID: 33629336 DOI: 10.26355/eurrev\_202102\_24877]

149 **Mahallawi WH**, Mumena WA. Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines. *Front Immunol* 2021; **12**: 794642 [PMID: 34925378 DOI: 10.3389/fimmu.2021.794642]

150 **Polack FP**, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603-2615 [PMID: 33301246 DOI: 10.1056/NEJMoa2034577]

151 **Lazarus R**, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA; ComfluCOV Trial Group. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. *Lancet* 2021; **398**: 2277-2287 [PMID: 34774197 DOI: 10.1016/S0140-6736(21)02329-1]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 11, 2022

**First decision:** October 19, 2022

**Article in press:** November 19, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Cozma CT, Romania; Samadder S, India **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:** Wang JJ

**Figure Legends**



**Figure 1 Flow diagram of literature search.**



**Figure 2 Pie-chart distribution by country of the 57 included studies.**

**Table 1 Characteristics of included studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Site** | **Sample size (*n*)** | **No. of patients with HBV infection, *n* (%)** | **Major serum biochemical characteristics of co-infected patients** | **Outcomes** | |
| **Death, *n* (%)** | **Survival, *n* (%)** |
| Guan *et al*[53] | China | 1590 | 28 (1.8) | NR | 1 (3.6) | 27 (96.4) |
| Zou *et al*[2] | China | 93 | 93 (100.0) | Abnormal liver function | 7 (7.5) | 86 (92.5) |
| Song *et al*[47] | China | 4 | 2 (50.0) | Abnormal blood parameters | 0 (0.0) | 2 (100.0) |
| Qi *et al*[10] | China | 3 | 1 (33.3) | Abnormal liver enzyme | 1 (100) | 0 (0.0) |
| Hambali *et al*[11] | Malaysia | 1 | 1 (100.0) | Abnormal liver enzyme | 0 (0.0) | 1 (100.0) |
| Ali *et al*[12] | Qatar | 1 | 1 (100.0) | Elevated liver enzymes | 1 (100) | 0 (0.0) |
| Zha *et al*[13] | China | 31 | 2 (6.5) | Elevated liver enzymes | 0 (0.0) | 2 (100.0) |
| Cai *et al*[14] | China | 298 | 5 (1.7) | Elevated liver enzymes | NR | NR |
| Naderi *et al*[15] | Iran | 931 | 13 (13.8)2 | Elevated liver enzymes | 0 (0.0) | 13 (100.0) |
| Yip *et al*[16] | Hong Kong SAR, China | 5639 | 353 (6.3)3 | ALT abnormality | 8 (2.3) | 345 (97.7) |
| Richardson *et al*[17] | United States | 5700 | 8 (0.1) | Elevated liver enzymes | NA | NA |
| Kang *et al*[54] | Korea | 7723 | 267 (3.5) | NR | 12 (5.1) | 255 (94.9) |
| Li *et al*[18] | China | 7 | 7 (100.0) | Elevated liver enzymes | 0 (0.0) | 7 (100.0) |
| Chen *et al*[9] | China | 123 | 15 (12.2) | Abnormal liver enzyme | 2 (13.3) | 13 (86.7) |
| Bongiovanni *et al*[19] | Italy | 1 | 1 (100.0) | Liver enzymes increased | 0 (0.0) | 1 (100.0) |
| He *et al*[20] | China | 571 | 15 (2.6) | Liver enzymes increased | 0 (0.0) | 15 (100.0) |
| Wen *et al*[21] | China | 110 | 5 (4.5) | Abnormal liver enzyme | NA | NA |
| Zou *et al*[7] | China | 105 | 105 (100.0) | Liver enzymes increased | 98 (93.3) | 7 (6.7) |
| Wang *et al*[8] | China | 436 | 109 (25.0) | Abnormal liver enzyme system | 13 (11.93) | 96 (88.1) |
| Chen *et al*[5] | China | 326 | 20 (6.1) | Lower level of prealbumin | 0 (0.0) | 20 (100.0) |
| Zhang *et al*[22] | China | 23 | 23 (100.0) | Liver enzymes increased | 0 (0.0) | 23 (100.0) |
| Liu *et al*[48] | China | 220 | 50 (22.7) | Abnormal blood parameters | 4 (8) | 46 (92.0) |
| Yu *et al*[6] | China | 67 | 7 (10.4) | No significant change | 0 (0.0) | 7 (100.0) |
| Liu *et al*[23] | China | 714 | 20 (28.2)4 | Abnormal liver enzyme system | 0 (0.0) | 20 (100.0) |
| Lin *et al*[24] | China | 133 | 17 (12.8) | Liver enzymes increased | NR | NR |
| Bekçibaşı and Arslan[25] | Turkey | 156 | 20 (12.8) | Liver enzymes increased | 0 (0.0) | 20 (100.0) |
| Colaneri *et al*[26] | Italy | 1 | 1 (100.0) | Liver enzymes increased | 0 (0.0) | 1 (100.0) |
| Ma *et al*[50] | China | 109 | 1 (0.9) | Normal liver enzymes | NA | NA |
| Chen *et al*[27] | China | 274 | 11 (4.0) | Abnormal liver function | 5 (45.5) | 6 (54.5) |
| Ding *et al*[28] | China | 2073 | 134 (6.5) | Liver enzymes increased | 8 (6.0) | 126 (94.0) |
| Rodríguez-Tajes *et al*[29] | Spain | 484 | 72 (14.9) | Liver enzymes increased | 8 (11.1) | 64 (88.9) |
| Parlar *et al*[51] | Turkey | 4795 | 43 (9.0)2 | No significant change | 0 (0.0) | 43 (100.0) |
| Yang *et al*[30] | China | 2899 | 105 (3.6) | Liver enzymes increased | 18 (17.1) | 87 (82.9) |
| Yigit *et al*[31] | Qatar | 1 | 1 (100.0) | Liver enzymes increased | 1 (100) | 0 (0.0) |
| Aldhaleei *et al*[32] | United Arab Emirates | 1 | 1 (100.0) | Liver enzymes increased | 0 (0.0) | 1 (100.0) |
| Ji *et al*[33] | China | 140 | 7 (5.0) | Liver enzymes increased | 0 (0.0) | 7 (100.0) |
| Kim *et al*[34] | United States | 867 | 62 (7.2) | Liver enzymes increased | 5 (8.1) | 57 (91.9) |
| Wang *et al*[35] | China | 1 | 1 (100.0) | Abnormal liver enzyme system | 0 (0.0) | 1 (100.0) |
| Zhong *et al*[36] | China | 2 | 1 (50.0) | Liver enzymes increased | 0 (0.0) | 1 (100.0) |
| Fernández-Ruiz *et al*[49] | Spain | 18 | 2 (11.1) | Decreased white blood cells | 1 (50.0) | 1 (50.0) |
| Huang *et al*[37] | China | 1 | 1 (100.0) | Elevated total bilirubin | 1 (100) | 0 (0.0) |
| Patrono *et al*[57] | Italy | 10 | 2 (20.0) | NR | 0 (0.0) | 2 (100.0) |
| Qin *et al*[38] | China | 1 | 1 (100.0) | Abnormal liver enzyme system | 0 (0.0) | 1 (100.0) |
| Liu *et al*[58] | China | 1 | 1 (100.0) | NR | 0 (0.0) | 1 (100.0) |
| Loinaz *et al*[39] | Spain | 19 | 4 (21.1) | Abnormal liver enzyme system | 1 (25.0) | 3 (75.0) |
| Adali *et al*[40] | Turkey | 231 | 77 (33.3) | Abnormal liver enzyme system | 6 (7.8) | 71 (92.2) |
| Oruç *et al*[55] | Turkey | 92 | 4 (4.3) | NR | 0 (0.0) | 4 (100.0) |
| Guardigni *et al*[56] | Italy | 606 | 12 (2.0) | NR | NA | NA |
| Sagnelli *et al*[41] | Italy | 1 | 1 (100.0) | Liver enzymes increased | 1 (100) | 0 (0.0) |
| Lens *et al*[59] | Spain | 17645 | 9 (0.5)2 | NR | 0 (0.0) | 9 (100.0) |
| Phipps *et al*[42] | United States | 2273 | 15 (0.7) | Abnormal liver enzyme system | NA | NA |
| Li *et al*[52] | China | 85 | 2 (2.4) | Normal liver enzymes | 0 (0.0) | 2 (100.0) |
| Wu *et al*[43] | China | 1 | 1 (100.0) | Elevated liver enzyme | 0 (0.0) | 1 (100.0) |
| Wu *et al*[44] | China | 620 | 70 (11.3) | Elevated liver enzymes | 0 (0.0) | 70 (100.0) |
| Iavarone *et al*[45] | Italy | 50 | 5 (10.0) | Elevated liver enzymes | NA | NA |
| Marjot *et al*[60] | United Kingdom | 745 | 96 (12.9) | NR | 23 (24.0) | 73 (76.0) |
| Huang *et al*[46] | China | 1 | 1 (100.0) | Elevated liver enzymes | 0 (0.0) | 1 (100.0) |
| Total | 57 | 37375 | 1932 |  |  |  |

193 cases were the sample size of the experimental group and that of the other healthy control group was 62 cases. 93 cases were all chronic hepatitis B patients.

2Patients with co-infection with hepatitis B virus and severe acute respiratory syndrome coronavirus 2.

3The 353 cases were patients with current co-infection with hepatitis B virus (HBV), and another 359 patients with past infection with HBV were not included.

4Sample size after propensity score matching.

5All were chronic hepatitis B patients.

No.: Number; NA: Data not available; NR: Data not reported; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**